Loading...

De La Maza, Luis M

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentPathology
Address1001 Health Sciences Road
CA 92697-3950
Phone(949) 824-7450
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Trapping membrane proteins with adjuvant-carrying amphipols for vaccine formulati
    NIH/NIAID R01AI092129Sep 1, 2011 - Aug 31, 2015
    Role: Principal Investigator
    Evaluation of a subunit Chlamydia trachomatis vaccine in Rhesus Macaques
    NIH/NIAID R56AI093953Sep 1, 2011 - Aug 31, 2013
    Role: Principal Investigator
    Scanning Chlamydia proteome for vaccine antigens
    NIH/NIAID R42AI072847Apr 15, 2007 - Jun 30, 2012
    Role: Principal Investigator
    Scanning Chlamydia proteome for vaccine antigens
    NIH/NIAID R41AI072847Apr 15, 2007 - Sep 16, 2009
    Role: Principal Investigator
    Recombinant C. trachomatis vaccine
    NIH/NIAID R01AI067888Mar 16, 2007 - Feb 28, 2013
    Role: Principal Investigator
    Immunopathology of Tubal Infertility
    NIH/NIAID R01AI032248Jan 1, 1993 - Jan 31, 2010
    Role: Principal Investigator
    RECOMBINANT POLYTYPIC CHLAMYDIA VACCINE
    NIH/NIAID R01AI026807Sep 1, 1989 - Aug 31, 1993
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pal S, Tifrea DF, Zhong G, de la Maza LM. Transcervical Inoculation with Chlamydia trachomatis Induces Infertility in HLA-DR4 Transgenic and Wild-Type Mice. Infect Immun. 2018 01; 86(1). PMID: 29038126.
      View in: PubMed
    2. Zhong G, Brunham RC, de la Maza LM, Darville T, Deal C. National Institute of Allergy and Infectious Diseases workshop report: "Chlamydia vaccines: The way forward". Vaccine. 2017 Oct 31. PMID: 29097007.
      View in: PubMed
    3. Pickering H, Teng A, Faal N, Joof H, Makalo P, Cassama E, Nabicassa M, Last AR, Burr SE, Rowland-Jones SL, Thomson NR, Roberts CH, Mabey DCW, Bailey RL, Hayward RD, de la Maza LM, Holland MJ. Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infection. Sci Rep. 2017 Aug 29; 7(1):9634. PMID: 28851925.
      View in: PubMed
    4. De La Maza L, Wu M, Wu L, Yun H, Zhao Y, Cattral M, McCart A, Cho BJ, de Perrot M. In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model. Clin Cancer Res. 2017 Sep 15; 23(18):5502-5513. PMID: 28606922.
      View in: PubMed
    5. de la Maza LM, Zhong G, Brunham RC. Update on Chlamydia trachomatis Vaccinology. Clin Vaccine Immunol. 2017 Apr; 24(4). PMID: 28228394.
      View in: PubMed
    6. Pal S, Favaroni A, Tifrea DF, Hanisch PT, Luczak SET, Hegemann JH, de la Maza LM. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge. Vaccine. 2017 05 02; 35(19):2543-2549. PMID: 28385608.
      View in: PubMed
    7. Pal S, Tifrea DF, Follmann F, Andersen P, de la Maza LM. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. Vaccine. 2017 03 23; 35(13):1705-1711. PMID: 28238632.
      View in: PubMed
    8. Visan L, Sanchez V, Kania M, de Montfort A, de la Maza LM, Ausar SF. Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis. Hum Vaccin Immunother. 2016 09; 12(9):2341-50. PMID: 27104338.
      View in: PubMed
    9. Tifrea DF, Barta ML, Pal S, Hefty PS, de la Maza LM. Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen. Microbes Infect. 2016 Apr; 18(4):245-53. PMID: 26706820.
      View in: PubMed
    10. Pal S, Tatarenkova OV, de la Maza LM. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge. Immunology. 2015 Nov; 146(3):432-43. PMID: 26423798; PMCID: PMC4610632 [Available on 11/01/16].
    11. Wu L, Wu MO, De la Maza L, Yun Z, Yu J, Zhao Y, Cho J, de Perrot M. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget. 2015 May 20; 6(14):12468-80. PMID: 25980578; PMCID: PMC4494951.
    12. Wu L, Yun Z, Tagawa T, De la Maza L, Wu MO, Yu J, Zhao Y, de Perrot M. Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma. Cancer Immunol Immunother. 2014 Dec; 63(12):1285-96. PMID: 25183171.
      View in: PubMed
    13. Feinstein HE, Tifrea D, Sun G, Popot JL, de la Maza LM, Cocco MJ. Long-term stability of a vaccine formulated with the amphipol-trapped major outer membrane protein from Chlamydia trachomatis. J Membr Biol. 2014 Oct; 247(9-10):1053-65. PMID: 24942817; PMCID: PMC4198661.
    14. Patton DL, Teng A, Randall A, Liang X, Felgner PL, de la Maza LM. Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques. J Proteomics. 2014 Aug 28; 108:99-109. PMID: 24862987; PMCID: PMC4112733.
    15. Tifrea DF, Pal S, Popot JL, Cocco MJ, de la Maza LM. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum. J Immunol. 2014 Jun 01; 192(11):5201-13. PMID: 24778450; PMCID: PMC4030638.
    16. Al-Kuhlani M, Rothschild J, Rothchild J, Pal S, de la Maza LM, Ouburg S, Morré SA, Dean D, Ojcius DM. TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans. PLoS One. 2014; 9(4):e93939. PMID: 24695582; PMCID: PMC3973638.
    17. Cheng C, Pal S, Tifrea D, Jia Z, de la Maza LM. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect. 2014 Mar; 16(3):244-52. PMID: 24291713.
      View in: PubMed
    18. Cheng C, Jain P, Pal S, Tifrea D, Sun G, Teng AA, Liang X, Felgner PL, de la Maza LM. Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582). Microbes Infect. 2014 Feb; 16(2):123-133. PMID: 24161793.
      View in: PubMed
    19. Tifrea DF, Pal S, Toussi DN, Massari P, de la Maza LM. Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge. Microbes Infect. 2013 Nov; 15(13):920-7. PMID: 23999313; PMCID: PMC3842390.
    20. Feher VA, Randall A, Baldi P, Bush RM, de la Maza LM, Amaro RE. A 3-dimensional trimeric ß-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram-negative bacterial porins. PLoS One. 2013; 8(7):e68934. PMID: 23935908; PMCID: PMC3723809.
    21. Pal S, de la Maza LM. Mechanism of T-cell mediated protection in newborn mice against a Chlamydia infection. Microbes Infect. 2013 Jul-Aug; 15(8-9):607-14. PMID: 23644176.
      View in: PubMed
    22. Tifrea DF, Ralli-Jain P, Pal S, de la Maza LM. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun. 2013 May; 81(5):1741-50. PMID: 23478318; PMCID: PMC3648024.
    23. Carmichael JR, Tifrea D, Pal S, de la Maza LM. Differences in infectivity and induction of infertility: a comparative study of Chlamydia trachomatis strains in the murine model. Microbes Infect. 2013 Mar; 15(3):219-29. PMID: 23287699; PMCID: PMC3602122.
    24. Massari P, Toussi DN, Tifrea DF, de la Maza LM. Toll-like receptor 2-dependent activity of native major outer membrane protein proteosomes of Chlamydia trachomatis. Infect Immun. 2013 Jan; 81(1):303-10. PMID: 23132491; PMCID: PMC3536141.
    25. Teng A, Cruz-Fisher MI, Cheng C, Pal S, Sun G, Ralli-Jain P, Molina DM, Felgner PL, Liang X, de la Maza LM. Proteomic identification of immunodominant chlamydial antigens in a mouse model. J Proteomics. 2012 Dec 21; 77:176-86. PMID: 22959960; PMCID: PMC3575745.
    26. Cheng C, Jain P, Bettahi I, Pal S, Tifrea D, de la Maza LM. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine. 2011 Sep 02; 29(38):6641-9. PMID: 21742006; PMCID: PMC3156873.
    27. Carmichael JR, Pal S, Tifrea D, de la Maza LM. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine. 2011 Jul 18; 29(32):5276-83. PMID: 21609745; PMCID: PMC3139009.
    28. Tifrea DF, Sun G, Pal S, Zardeneta G, Cocco MJ, Popot JL, de la Maza LM. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine. 2011 Jun 20; 29(28):4623-31. PMID: 21550371; PMCID: PMC3114171.
    29. Cheng C, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine. 2011 Apr 18; 29(18):3456-64. PMID: 21376796; PMCID: PMC3084512.
    30. Cheng C, Cruz-Fisher MI, Tifrea D, Pal S, Wizel B, de la Maza LM. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31®. Vaccine. 2011 Mar 16; 29(13):2437-43. PMID: 21276442.
      View in: PubMed
    31. Cruz-Fisher MI, Cheng C, Sun G, Pal S, Teng A, Molina DM, Kayala MA, Vigil A, Baldi P, Felgner PL, Liang X, de la Maza LM. Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice. Infect Immun. 2011 Jan; 79(1):246-57. PMID: 20956570; PMCID: PMC3019893.
    32. Pal S, Sarcon AK, de la Maza LM. A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males. Vaccine. 2010 Nov 10; 28(48):7606-12. PMID: 20920574; PMCID: PMC2981627.
    33. Ralli-Jain P, Tifrea D, Cheng C, Pal S, de la Maza LM. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine. 2010 Nov 10; 28(48):7659-66. PMID: 20875490; PMCID: PMC2981640.
    34. Pal S, Tatarenkova O, de la Maza LM. Maternal immunity partially protects newborn mice against a Chlamydia trachomatis intranasal challenge. J Reprod Immunol. 2010 Nov; 86(2):151-7. PMID: 20554327; PMCID: PMC2949516.
    35. Chu H, Slepenkin A, Elofsson M, Keyser P, de la Maza LM, Peterson EM. Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. Int J Antimicrob Agents. 2010 Aug; 36(2):145-50. PMID: 20605703; PMCID: PMC2902681.
    36. Molina DM, Pal S, Kayala MA, Teng A, Kim PJ, Baldi P, Felgner PL, Liang X, de la Maza LM. Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine. 2010 Apr 09; 28(17):3014-24. PMID: 20044059; PMCID: PMC3048468.
    37. Pal S, Sarcon AK, de la Maza LM. C3H male mice with severe combined immunodeficiency cannot clear a urethral infection with a human serovar of Chlamydia trachomatis. Infect Immun. 2009 Dec; 77(12):5602-7. PMID: 19805533; PMCID: PMC2786464.
    38. Cai S, He F, Samra HS, de la Maza LM, Bottazzi ME, Joshi SB, Middaugh CR. Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Mol Pharm. 2009 Sep-Oct; 6(5):1553-61. PMID: 19650664; PMCID: PMC2757499.
    39. Cheng C, Bettahi I, Cruz-Fisher MI, Pal S, Jain P, Jia Z, Holmgren J, Harandi AM, de la Maza LM. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine. 2009 Oct 19; 27(44):6239-46. PMID: 19686693; PMCID: PMC3566636.
    40. Kari L, Whitmire WM, Crane DD, Reveneau N, Carlson JH, Goheen MM, Peterson EM, Pal S, de la Maza LM, Caldwell HD. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol. 2009 Jun 15; 182(12):8063-70. PMID: 19494332.
      View in: PubMed
    41. Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine. 2009 Aug 06; 27(36):5020-5. PMID: 19446590; PMCID: PMC2741729.
    42. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17; 29(4):602-14. PMID: 18835197; PMCID: PMC2732399.
    43. Pal S, Bravo J, Peterson EM, de la Maza LM. Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect Immun. 2008 Dec; 76(12):5581-7. PMID: 18809664; PMCID: PMC2583570.
    44. Sun G, Pal S, Sarcon AK, Kim S, Sugawara E, Nikaido H, Cocco MJ, Peterson EM, de la Maza LM. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J Bacteriol. 2007 Sep; 189(17):6222-35. PMID: 17601785; PMCID: PMC1951919.
    45. Slepenkin A, Enquist PA, Hägglund U, de la Maza LM, Elofsson M, Peterson EM. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun. 2007 Jul; 75(7):3478-89. PMID: 17470544; PMCID: PMC1932962.
    46. Pal S, Schmidt AP, Peterson EM, Wilson CL, de la Maza LM. Role of matrix metalloproteinase-7 in the modulation of a Chlamydia trachomatis infection. Immunology. 2006 Feb; 117(2):213-9. PMID: 16423057; PMCID: PMC1782213.
    47. Pal S, Peterson EM, de la Maza LM. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun. 2005 Dec; 73(12):8153-60. PMID: 16299310; PMCID: PMC1307068.
    48. Pal S, Peterson EM, Rappuoli R, Ratti G, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine. 2006 Feb 06; 24(6):766-75. PMID: 16199110.
      View in: PubMed
    49. Pal S, Peterson EM, de la Maza LM. Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis. Vaccine. 2005 Nov 16; 23(46-47):5351-8. PMID: 16085340.
      View in: PubMed
    50. Lad SP, Fukuda EY, Li J, de la Maza LM, Li E. Up-regulation of the JAK/STAT1 signal pathway during Chlamydia trachomatis infection. J Immunol. 2005 Jun 01; 174(11):7186-93. PMID: 15905563.
      View in: PubMed
    51. Yen TY, Pal S, de la Maza LM. Characterization of the disulfide bonds and free cysteine residues of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Biochemistry. 2005 Apr 26; 44(16):6250-6. PMID: 15835913.
      View in: PubMed
    52. Slepenkin A, de la Maza LM, Peterson EM. Interaction between components of the type III secretion system of Chlamydiaceae. J Bacteriol. 2005 Jan; 187(2):473-9. PMID: 15629918; PMCID: PMC543553.
    53. Pal S, Peterson EM, de la Maza LM. New murine model for the study of Chlamydia trachomatis genitourinary tract infections in males. Infect Immun. 2004 Jul; 72(7):4210-6. PMID: 15213165; PMCID: PMC427456.
    54. Pal S, Peterson EM, de la Maza LM. Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice. Immunology. 2003 Nov; 110(3):368-75. PMID: 14632665; PMCID: PMC1783049.
    55. Slepenkin A, Motin V, de la Maza LM, Peterson EM. Temporal expression of type III secretion genes of Chlamydia pneumoniae. Infect Immun. 2003 May; 71(5):2555-62. PMID: 12704128; PMCID: PMC153279.
    56. Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine. 2003 Mar 28; 21(13-14):1455-65. PMID: 12615442.
      View in: PubMed
    57. Pal S, Davis HL, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun. 2002 Sep; 70(9):4812-7. PMID: 12183524; PMCID: PMC128273.
    58. de la Maza LM, Peterson EM. Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs. 2002 Jul; 3(7):980-6. PMID: 12186275.
      View in: PubMed
    59. Rodríguez-Marañón MJ, Bush RM, Peterson EM, Schirmer T, de la Maza LM. Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia. Protein Sci. 2002 Jul; 11(7):1854-61. PMID: 12070338; PMCID: PMC2373662.
    60. Tapia O, Slepenkin A, Sevrioukov E, Hamor K, de la Maza LM, Peterson EM. Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae. Clin Diagn Lab Immunol. 2002 May; 9(3):562-7. PMID: 11986260; PMCID: PMC119991.
    61. Shigei J, Tan G, Shiao A, de la Maza LM, Peterson EM. Comparison of two commercially available selective media to screen for vancomycin-resistant enterococci. Am J Clin Pathol. 2002 Jan; 117(1):152-5. PMID: 11789720.
      View in: PubMed